BNP Paribas Financial Markets’s SpringWorks Therapeutics SWTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,474	Closed	-$257K	–	5763
2025 Q2	$257K	Sell	5,474 -207	-4%	-$9.21K	﹤0.01%	3680
2025 Q1	$251K	Sell	5,681 -4,038	-42%	-$186K	﹤0.01%	3585
2024 Q4	$351K	Buy	+9,719	New	+$340K	﹤0.01%	3519

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BNP Paribas Financial Markets's SWTX Position: Q3 2025 in Review

BNP Paribas Financial Markets sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 5,474 shares — an estimated $257K sold.

BNP Paribas Financial Markets first reported a position in SWTX in Q4 2024 and held it in 3 quarters. The position peaked at $351K in Q4 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

BNP Paribas Financial Markets reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
BNP Paribas Financial Markets sold 5,474 SpringWorks Therapeutics shares in Q3 2025, an estimated $257K.
BNP Paribas Financial Markets first reported a position in SpringWorks Therapeutics in Q4 2024 and held it in 3 quarters.
BNP Paribas Financial Markets's SpringWorks Therapeutics position peaked at $351K in Q4 2024.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.